SCM
ARRY

Sarissa Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Sarissa Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-4,300,000
Closed -$29M – 14
2016
Q3 		$29M Hold
4,300,000
– – 6.68% 4
2016
Q2 		$15.3M Buy
4,300,000
+1,425,000
+50% +$4.64M 4.35% 7
2016
Q1 		$8.48M Buy
2,875,000
+2,175,000
+311% +$6.52M 1.87% 11
2015
Q4 		$2.95M Buy
+700,000
New +$3.19M 0.57% 12

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Sarissa Capital Management's ARRY Position: Q4 2016 in Review

Sarissa Capital Management sold out of Array Biopharma Inc (ARRY) in Q4 2016, closing a stake of 4,300,000 shares — an estimated $29M sold.

Sarissa Capital Management first reported a position in ARRY in Q4 2015 and held it in 4 quarters. The position peaked at $29M in Q3 2016. 167 funds tracked by Wall St. Rank hold ARRY as of Q4 2016.

  • Sarissa Capital Management reported no remaining Array Biopharma Inc position as of Q4 2016 after selling out during the quarter.
  • Sarissa Capital Management sold 4,300,000 Array Biopharma Inc shares in Q4 2016, an estimated $29M.
  • Sarissa Capital Management first reported a position in Array Biopharma Inc in Q4 2015 and held it in 4 quarters.
  • Sarissa Capital Management's Array Biopharma Inc position peaked at $29M in Q3 2016.
  • 167 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2016.

Based on Sarissa Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.